Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $420

Benzinga Newsdesk www.benzinga.com Positive 78.8%

Neg 0% Neu 0% Pos 78.8%

Guggenheim analyst Michael Schmidt maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $410 to $420.